Engineered DNA-encoded PCSK9 Inhibitors May Provide an Effective Alternative for Treating High Cholesterol

Researchers at The Wistar Institute have developed novel synthetic DNA-encoded monoclonal antibodies (DMAbs) directed against PCSK9, a protein key to regulating cholesterol levels in the bloodstream.
5-Dec-2018 3:30 PM EST Add to Favorites

Function of Neutrophils During Tumor Progression Unraveled

Wistar researchers have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and facilitate tumor cell seeding and...
15-Oct-2018 8:05 AM EDT Add to Favorites

Synthetic DNA Vaccine Against Ebola Virus Shows Potent and Long-term Efficacy in Preclinical Studies

A novel synthetic DNA vaccine developed based on technology pioneered by Wistar scientists offers complete protection from Zaire Ebolavirus (EBOV) infection in promising preclinical research.
10-Oct-2018 9:10 AM EDT Add to Favorites

Mechanism of Resistance to Novel Targeted Therapy for Ovarian Cancer Identified

Wistar scientists have unraveled a mechanism of resistance to EZH2 inhibitors in ovarian cancers with mutations in the ARID1A gene.
8-Oct-2018 10:05 AM EDT Add to Favorites

Engineered Synthetic DNA-Encoded Checkpoint Inhibitor Antibodies Advance the Field of Cancer Immunotherapy

Wistar scientists and collaborators demonstrate for the first time that through engineering constructs, they can express DNA-encoded monoclonal antibodies (DMAbs) targeting CTLA-4, an important cancer checkpoint molecule that blocks anti-cancer...
4-Oct-2018 10:05 AM EDT Add to Favorites

Targeting Multiple Members of a Family of Tumor Antigens with a Synthetic DNA Vaccine Shows Promise for Cancer Immunotherapy

Wistar scientists have implemented a novel structurally designed synthetic DNA vaccine to simultaneously target multiple members of a family of proteins that are specifically overexpressed in several types of cancer.
27-Sep-2018 11:15 AM EDT Add to Favorites

Virion Therapeutics, LLC Raises $5 Million to Develop Checkpoint Inhibitor Powered Vaccine Therapies for Treatment of Virally Induced Infectious Diseases & Cancers

A new Philadelphia-based start-up, Virion Therapeutics, LLC spun out of The Wistar Institute, will work to advance innovative, immune-based therapies for the treatment of chronic viral-associated cancers and viral infections utilizing the first...
26-Sep-2018 10:05 AM EDT Add to Favorites

Synthetic DNA Vaccine Effective Against Influenza A Virus Subtype That Is Responsible for More Severe Influenza Seasons

Wistar scientists have engineered a synthetic DNA vaccine shown to produce broad immune responses against these H3N2 viruses.
6-Sep-2018 1:15 PM EDT Add to Favorites

see all news